|
1
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2016. CA Cancer J Clin. 66:7–30. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Kienast Y, von Baumgarten L, Fuhrmann M,
Klinkert WE, Goldbrunner R, Herms J and Winkler F: Real-time
imaging reveals the single steps of brain metastasis formation. Nat
Med. 16:116–122. 2010. View
Article : Google Scholar : PubMed/NCBI
|
|
3
|
Palmieri D, Smith QR, Lockman PR, Bronder
J, Gril B, Chambers AF, Weil RJ and Steeg PS: Brain metastases of
breast cancer. Breast Dis. 26:139–147. 2006-2007. View Article : Google Scholar
|
|
4
|
Kodack DP, Askoxylakis V, Ferraro GB,
Fukumura D and Jain RK: Emerging strategies for treating brain
metastases from breast cancer. Cancer Cell. 27:163–175. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Rostami R, Mittal S, Rostami P, Tavassoli
F and Jabbari B: Brain metastasis in breast cancer: A comprehensive
literature review. J Neurooncol. 127:407–414. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Sihto H, Lundin J, Lundin M, Lehtimäki T,
Ristimäki A, Holli K, Sailas L, Kataja V, Turpeenniemi-Hujanen T,
Isola J, et al: Breast cancer biological subtypes and protein
expression predict for the preferential distant metastasis sites: A
nationwide cohort study. Breast Cancer Res. 13:R872011. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Gil-Gil MJ, Martinez-Garcia M, Sierra A,
Conesa G, Del Barco S, González-Jimenez S and Villà S: Breast
cancer brain metastases: A review of the literature and a current
multidisciplinary management guideline. Clin Transl Oncol.
16:436–446. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Lam SW, Jimenez CR and Boven E: Breast
cancer classification by proteomic technologies: Current state of
knowledge. Cancer Treat Rev. 40:129–138. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Yoneda T, Williams PJ, Hiraga T, Niewolna
M and Nishimura R: A bone-seeking clone exhibits different
biological properties from the MDA-MB-231 parental human breast
cancer cells and a brain-seeking clone in vivo and in vitro. J Bone
Miner Res. 16:1486–1495. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Stark AM, Anuszkiewicz B, Mentlein R,
Yoneda T, Mehdorn HM and Held-Feindt J: Differential expression of
matrix metalloproteinases in brain- and bone-seeking clones of
metastatic MDA-MB-231 breast cancer cells. J Neurooncol. 81:39–48.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Dun MD, Chalkley RJ, Faulkner S, Keene S,
Avery-Kiejda KA, Scott RJ, Falkenby LG, Cairns MJ, Larsen MR,
Bradshaw RA, et al: Proteotranscriptomic profiling of 231-BR breast
cancer cells: Identification of potential biomarkers and
therapeutic targets for brain metastasis. Mol Cell Proteomics.
14:2316–2330. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Fitzgerald DP, Subramanian P, Deshpande M,
Graves C, Gordon I, Qian Y, Snitkovsky Y, Liewehr DJ, Steinberg SM,
Paltán-Ortiz JD, et al: Opposing effects of pigment
epithelium-derived factor on breast cancer cell versus neuronal
survival: Implication for brain metastasis and metastasis-induced
brain damage. Cancer Res. 72:144–153. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Gril B, Palmieri D, Bronder JL, Herring
JM, Vega-Valle E, Feigenbaum L, Liewehr DJ, Steinberg SM, Merino
MJ, Rubin SD, et al: Effect of lapatinib on the outgrowth of
metastatic breast cancer cells to the brain. J Natl Cancer Inst.
100:1092–1103. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Lockman PR, Mittapalli RK, Taskar KS,
Rudraraju V, Gril B, Bohn KA, Adkins CE, Roberts A, Thorsheim HR,
Gaasch JA, et al: Heterogeneous blood-tumor barrier permeability
determines drug efficacy in experimental brain metastases of breast
cancer. Clin Cancer Res. 16:5664–5678. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Palmieri D, Bronder JL, Herring JM, Yoneda
T, Weil RJ, Stark AM, Kurek R, Vega-Valle E, Feigenbaum L,
Halverson D, et al: Her-2 overexpression increases the metastatic
outgrowth of breast cancer cells in the brain. Cancer Res.
67:4190–4198. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Percy DB, Ribot EJ, Chen Y, McFadden C,
Simedrea C, Steeg PS, Chambers AF and Foster PJ: In vivo
characterization of changing blood-tumor barrier permeability in a
mouse model of breast cancer metastasis: A complementary magnetic
resonance imaging approach. Invest Radiol. 46:718–725.
2011.PubMed/NCBI
|
|
17
|
Chen G and Davies MA: Emerging insights
into the molecular biology of brain metastases. Biochem Pharmacol.
83:305–314. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Zarzynska JM: Two faces of TGF-beta1 in
breast cancer. Mediators Inflamm. 2014:1417472014. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Shibanuma M, Mashimo J, Mita A, Kuroki T
and Nose K: Cloning from a mouse osteoblastic cell line of a set of
transforming-growth-factor-beta 1-regulated genes, one of which
seems to encode a follistatin-related polypeptide. Eur J Biochem.
217:13–19. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Adams D, Larman B and Oxburgh L:
Developmental expression of mouse Follistatin-like 1 (Fstl1):
Dynamic regulation during organogenesis of the kidney and lung.
Gene Expr Patterns. 7:491–500. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Kawabata D, Tanaka M, Fujii T, Umehara H,
Fujita Y, Yoshifuji H, Mimori T and Ozaki S: Ameliorative effects
of follistatin-related protein/TSC-36/FSTL1 on joint inflammation
in a mouse model of arthritis. Arthritis Rheum. 50:660–668. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Xi Y, Gong DW and Tian Z: FSTL1 as a
potential mediator of exercise-induced cardioprotection in
post-myocardial infarction rats. Sci Rep. 6:324242016. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Reddy SP, Britto R, Vinnakota K, Aparna H,
Sreepathi HK, Thota B, Kumari A, Shilpa BM, Vrinda M, Umesh S, et
al: Novel glioblastoma markers with diagnostic and prognostic value
identified through transcriptome analysis. Clin Cancer Res.
14:2978–2987. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Kudo-Saito C, Fuwa T, Murakami K and
Kawakami Y: Targeting FSTL1 prevents tumor bone metastasis and
consequent immune dysfunction. Cancer Res. 73:6185–6193. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Chan QK, Ngan HY, Ip PP, Liu VW, Xue WC
and Cheung AN: Tumor suppressor effect of follistatin-like 1 in
ovarian and endometrial carcinogenesis: A differential expression
and functional analysis. Carcinogenesis. 30:114–121. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Chaly Y, Hostager B, Smith S and Hirsch R:
Follistatin-like protein 1 and its role in inflammation and
inflammatory diseases. Immunol Res. 59:266–272. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Chen SX, Xu XE, Wang XQ, Cui SJ, Xu LL,
Jiang YH, Zhang Y, Yan HB, Zhang Q, Qiao J, et al: Identification
of colonic fibroblast secretomes reveals secretory factors
regulating colon cancer cell proliferation. J Proteomics.
110:155–171. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Bae K, Park KE, Han J, Kim J, Kim K and
Yoon KA: Mitotic cell death caused by follistatin-like 1 inhibition
is associated with up-regulated Bim by inactivated Erk1/2 in human
lung cancer cells. Oncotarget. 7:18076–18084. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Tan J, Yang S, Shen P, Sun H, Xiao J, Wang
Y, Wu B, Ji F, Yan J, Xue H, et al: C-kit signaling promotes
proliferation and invasion of colorectal mucinous adenocarcinoma in
a murine model. Oncotarget. 6:27037–27048. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Meng X, Zheng R, Zhang Y, Qiao M, Liu L,
Jing P, Wang L, Liu J and Gao Y: An activated sympathetic nervous
system affects white adipocyte differentiation and lipolysis in a
rat model of Parkinson's disease. J Neurosci Res. 93:350–360. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Wieser R: The transforming growth
factor-beta signaling pathway in tumorigenesis. Curr Opin Oncol.
13:70–77. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Dong Y, Geng Y, Li L, Li X, Yan X, Fang Y,
Li X, Dong S, Liu X, Li X, et al: Blocking follistatin-like 1
attenuates bleomycin-induced pulmonary fibrosis in mice. J Exp Med.
212:235–252. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Geng Y, Dong Y, Yu M, Zhang L, Yan X, Sun
J, Qiao L, Geng H, Nakajima M, Furuichi T, et al: Follistatin-like
1 (Fstl1) is a bone morphogenetic protein (BMP) 4 signaling
antagonist in controlling mouse lung development. Proc Natl Acad
Sci USA. 108:pp. 7058–7063. 2011; View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Tan X, Zhai Y, Chang W, Hou J, He S, Lin
L, Yu Y, Xu D, Xiao J, Ma L, et al: Global analysis of
metastasis-associated gene expression in primary cultures from
clinical specimens of clear-cell renal-cell carcinoma. Int J
Cancer. 123:1080–1088. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Massagué J: TGFbeta in cancer. Cell.
134:215–230. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Tanaka M, Murakami K, Ozaki S, Imura Y,
Tong XP, Watanabe T, Sawaki T, Kawanami T, Kawabata D, Fujii T, et
al: DIP2 disco-interacting protein 2 homolog A (Drosophila) is a
candidate receptor for follistatin-related protein/follistatin-like
1 - analysis of their binding with TGF-β superfamily proteins. FEBS
J. 277:4278–4289. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Ouchi N, Asaumi Y, Ohashi K, Higuchi A,
Sono-Romanelli S, Oshima Y and Walsh K: DIP2A functions as a FSTL1
receptor. J Biol Chem. 285:7127–7134. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Soffietti R, Rudà R and Trevisan E: Brain
metastases: Current management and new developments. Curr Opin
Oncol. 20:676–684. 2008. View Article : Google Scholar : PubMed/NCBI
|
